

Carbetocin PharmIdea

100 micrograms/ml solution for injection

Carbetocin has been approved by EBCOG & SOGC for use immediately following an elective Cesarean section when a local or spinal anesthesia has been administered.

Pharmacological information. Carbetocin is a long-acting synthetic Oxytocin analogue.

Therapeutic indications. Carbetocin is indicated for the prevention of uterine atony following delivery of the infant by caesarean section under epidural or spinal anaesthesia.

Dosage and Administration. A single intravenous dose of 100 μg of Carbetocin injection is administered by injection, slowly over 1 minute, only when delivery of the infant has been completed by caesarean section under epidural or spinal anesthesia.

Carbetocin versus Oxytocin

Characteristics	Carbetocin 100 μg/ml	Oxytocin 201U in 1000 ml 0,9% NaCl
Administration	1 single i/v dosage	infusion 150 ml/hour
Therapeutical effect	less than 2 min after i/v	16 hours i/v infusion
Additional uterotonic agents	no need	need additional
Haemodynamic effects	hypotensive effect	greater hypotensive effect
Diuresis	higher	lower
Maternal adverse risk	lower	higher
Blood loss	lower	higher

Conclusions. A single intravenous dose of 100 μ g of carbetocin has been shown to be as effective as a 16-hour infusion of oxytocin in preventing intraoperative blood loss after Caesarean section.

Considering its potential advantages over oxytocin — Carbetocin is more rapid and longer duration of effect, lower volumes to administer.

Data source: Society of Obstetricians and Gynaecologists of Canada (SOGC). European Board and College of Obstetrics and Gynaecology (EBCOG).

Pharmacotherapeutic group: Oxytocin and analogues

ATC code: H01BB03

Store and transport refrigerated (2 °C-8 °C).

Store in the original package in order to protect from light. Do not freeze.

Manufacturer: PharmIdea SIA, 4 Rupnicu Str., Olaine, LV 2114, Latvia

www.pharmidea.lv pharmidea@pharmidea.lv

